|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||129.25 - 130.17|
|52-week range||105.26 - 143.90|
|Beta (5Y monthly)||0.12|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||2.84 (2.16%)|
|Ex-dividend date||11 Aug 2022|
|1y target est||N/A|
Merck (MRK) is set to make an upfront payment of $150 million to Orna for rights to the latter's circular RNA technology to make vaccines and therapeutics for infectious disease and oncology.
Pharma group alleges breach of non-compete agreement to delay start date of departing business development official
FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza as a combination therapy for patients with metastatic castration-resistant prostate cancer.